A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women

Menopause International

Volumn 14, Issue 2, 2008, Pages 70-77

  Heikkinen, Jorma ^a   Vaheri, Raija ^c   Haapalahti, Jouko ^b   Timonen, Ulla ^c  

^a OULU DEACONESS INSTITUTE   (Finland)

^b Orion Diagnostica Oy   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

Bone mineral density; Continuous combined hormone replacement therapy; Fracture; Menopause; Osteoporosis

Indexed keywords

ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; INDIVINA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL VALERATE; MEDROXYPROGESTERONE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VERTEBRA; BONE; ESTROGEN THERAPY; POSTMENOPAUSE OSTEOPOROSIS;

BONE AND BONES; BONE DENSITY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDROXYPROGESTERONE; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 54549093758     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/mi.2008.008008     Document Type: Article

References (36)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
2. European Medicines Agency. EMEA public statement on recent publications regarding hormone replacement therapy. London: EMEA, 2003. www.emasonline.org/ content/EMEA/EMEA-3-12-2003.pdf (last accessed 23 March 2007)
3. Heads of Medicines Agencies. Further advice on safety of hormone replacement therapy: no longer recommended as first choice for prevention of osteoporosis. HMA, 2003. http://www.hma.eu/uploads/media/3.dez.2003.pdf (last accessed 23 March 2007)
4. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007;56:231-248 (Pubitemid 46241755)
5. Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005;51:113-126 (Pubitemid 40726109)
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477 (Pubitemid 46556472)
7. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone-loss: a comparison of high and low dose estrogen-progestogen regimens. Osteoporosis Int 2000;11:929-937 (Pubitemid 32044073)
8. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004;10:95-102 (Pubitemid 39549720)
9. Heikkinen JE, Vaheri RT, Ahomaki SM, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol 2000;182:560-567 (Pubitemid 30207312)
10. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc 2005;11:145-151 (Pubitemid 43108781)
11. Ylikangas S, Backstrom T, Heikkinen J. Cost-effectiveness of continuous combined hormone replacement therapy in long-term use: economic evaluation based on a 9-year study in Finland. Curr Med Res Opin 2007;23:57-64 (Pubitemid 46191670)
12. Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc 2006;12:115-125 (Erratum J Br Menopause Soc 2006;12:174.) (Pubitemid 44424241)
13. Kröger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporos Int 1992;2:135-140
14. Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 2001;12:251-258 (Pubitemid 34912730)
15. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-954 (Pubitemid 126664250)
16. Suvanto-Luukkonen E, Risteli L, Sundstrom H, et al. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 1997;266:105-116 (Pubitemid 28034190)
17. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999;2:323-342
18. Heikkinen J, Haapalahti J. Effect of different dose options of continuous combined hormone therapy on bone and bone marker N-terminal propeptide of type I procollagen: results from a long-tern study in Finnish postmenopausal women. In: Genazzani AR, ed. Postmenopausal Osteoporosis: Hormone and Other Therapies. Controversial Issues in Climacteric Medicine. London, New York: Taylor & Francis, 2006:281-287
19. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999;130:897-904
20. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372-379 (Pubitemid 40487394)
21. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676 (Pubitemid 34533545)
22. Cauley JA, Robbins J, Chen Z, et al. for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738
23. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004;164:871-879 (Pubitemid 38520628)
24. Bone HG, Hosking D, Devogelaer JP, et al. for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199
25. van Geel TA, Geusens PP, Nagtzaam IF, et al. Risk factors for clinical fractures among postmenopausal women: a 10-year propective study. Menopause Int 2007;13:110-115
26. Greendale GA, Espeland M, Sloane S, et al. PEPI Safety Follow-Up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study. Arch Intern Med 2002;162:665-672
27. Eiken P, Kolthoff N, Pors Nielsen S. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996;19:p191S-3S (Pubitemid 26397222)
28. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451 (Pubitemid 40458828)
29. Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813-1819 (Pubitemid 41361882)
30. Simon JA. Does osteopenia warrant treatment? Menopause 2005;12:639-648
31. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822 (Pubitemid 33126923)
32. Van Geel ACM, Geusens PP, Nagtzaam IF, et al. Timing and risk factors for clinical fractures among postmenopausal women: a 5-year prospective study. BMC Med 2006;4:24 (Pubitemid 44608342)
33. Stevenson JC. HRT, osteoporosis and regulatory authorities. Quis custodiet ipsos custodies? Hum Reprod 2006;21:1665-1671
34. Lamy O, Krieg MA, Burckhardt P, Wasserfallen JB. An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women. Expert Opin Pharmacother 2003;4:1479-1488 (Pubitemid 37120894)
35. Radspieler H, Dambacher MA, Kissling R, Neff M. Is the amount of trabecular bone-loss dependent on bone mineral density? A study performed by three centres of osteoporosis using high resolution peripheral quantitative computed tomography. Eur J Med Res 2000;5:32-39
36. Holick MF. The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 2006;4:96-102 (Pubitemid 44623931)